Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

110
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
110

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

O-GlcNAcylated YTHDF2 promotes bladder cancer progression by regulating the tumor suppressor gene <i>PER1</i> via m<sup>6</sup>A modification.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences·2025
Same author

OTUD1 downregulates PD-L1 expression by deubiquitinating STAT3 and promotes the immune response in ccRCC.

Cellular oncology (Dordrecht, Netherlands)·2025
Same author

Analytical control strategy for biologics. Part II: Roadmap for development and implementation.

Journal of pharmaceutical sciences·2025
Same author

A telomere-to-telomere genome assembly coupled with multi-omic data provides insights into the evolution of hexaploid bread wheat.

Nature genetics·2025
Same author

CircST6GALNAC6 Inhibits Glycolysis of Bladder Cancer by Regulating PRKN/HK1 Signaling Pathway.

Molecular carcinogenesis·2025
Same author

Quality risk management and data integrity in R&D laboratories supporting CMC lifecycle of biological products.

Journal of pharmaceutical sciences·2024

相关实验视频

Updated: May 22, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.2K

生物制剂的分析控制策略. 第一部分:基金会.

Brent S Kendrick1, Krishnan Sampathkumar2, John P Gabrielson3

  • 1First Principles Biopharma, LLC, Louisville, CO, USA.

Journal of pharmaceutical sciences
|May 12, 2025
PubMed
概括

本评论概述了开发生物疗法强有力的分析控制策略的基本要素. 它强调采用综合方法来确保产品质量和有效的生命周期管理以蛋白质为基础的药物.

关键词:
分析方法开发 分析方法开发分析方法验证的分析方法验证.分析目标配置文件的分析.生物制剂 生物制剂 生物制剂控制战略 控制策略配方的强度 配方的强度方法资格认证 方法资格认证单克隆抗体是一种单克隆抗体.这就是QBDD.质量目标产品简介质量目标产品简介

更多相关视频

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
10:50

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

14.5K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

507

相关实验视频

Last Updated: May 22, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.2K
Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
10:50

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

14.5K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

507

科学领域:

  • 生物制药开发 生物制药开发
  • 分析化学 分析化学
  • 监管科学 监管科学

背景情况:

  • 生物疗法,尽管有不同的分子形状,但共享一个共同的药物开发途径.
  • 这一途径整合了控制策略,包括目标产品配置文件 (TPP),质量目标产品配置文件 (QTPP),表征,关键质量属性 (CQA) 和分析控制.
  • 现有的指南涉及具体的开发研究,但缺乏在综合框架内建立分析控制策略的全面指导.

研究的目的:

  • 介绍开发生物疗法综合分析控制策略的基本基础.
  • 为提供基于蛋白质的治疗方式的有效生命周期管理提供框架.
  • 作为两部分系列的第一部分,为后续的实施路线图奠定了基础.

主要方法:

  • 对生物开发的现有监管指南 (ICH,FDA,EMA) 的审查和综合.
  • 对生物制剂综合控制战略的组成部分的分析.
  • 确定建立分析控制策略至关重要的基本要素.

主要成果:

  • 生物疗法的发展需要一个综合控制战略.
  • 关键组件包括TPP,QTPP,广泛的表征,CQA识别和分析控制策略.
  • 开发分析控制战略的基本原则对于生命周期管理至关重要.

结论:

  • 建立一个全面的分析控制策略对于成功开发和生物疗法的生命周期管理至关重要.
  • 本评论提供了创建此类策略的基础知识.
  • 第二部分将详细介绍实施分析控制战略的相应阶段的路线图.